论文部分内容阅读
目的 制备一种不具有促红细胞生成作用的新型促红细胞生成素(EPO)的衍生肽(DEPO).方法 9-芴甲氧羰基(Fmoc)固相多肽合成法制备合成新型DEPO,质谱法检测鉴定DEPO相对分子质量,高效液相色谱法鉴定DEPO纯度.健康成年C57BL/6小鼠随机分为EPO(EPO 50 μg·kg-1) 组、DEPO低剂量(DEPO 50 μg·kg-1)组、DEPO高剂量(DEPO 500 μg·kg-1)组、生理盐水(生理盐水,0.2 mL)组和溶剂 (ACN+Milliq,0.2 mL) 组,隔日1次腹腔注射给药,各组于第3、7、14和30天取尾静脉血检测红细胞数变化,探究DEPO对促红细胞生成活性的影响.结果 合成了一个新型、由37个氨基酸构成的DEPO,相对分子质量为3814.8,纯度达95.25%.EPO组给药第3~30天红细胞数呈上升趋势,第14和30天较第3天显著增高(P<0.001).DEPO低剂量组和DEPO高剂量组红细胞数未见明显增高.结论 本研究合成了一种新型DEPO,其在体内不产生促红细胞生成的不良反应,具有一定的临床应用前景.“,”Aim To prepare a novel erythropoietin-derived peptide which is not erythropoietic. Methods A 37-aa novel EPO-derived peptide was synthesized by Fmoc Solid Phase Peptide Synthesis method, the molecular weight was detected by ESI-MS method and the purity was identified by HPLC method. To assess the hematopoietic activity, healthy adult C57BL/6 mice were intraperitoneally injected with DEPO, EPO, saline or solvent every other day for consequent 30 days. The blood samples were collected at the 3rd, 7th, 14th, 30th day from the caudal vein and the red blood cell (RBC) were counted. Results A 37-aa novel erythropoietin-derived peptide named derived peptide of erythropoietin (DEPO) was synthesized with a purity of 95.25%. The RBC count in EPO group was significantly elevated at the 14th and the 30th day compared with that of the 3rd day, whereas DEPO group showed no significant increase.Conclusion DEPO is a novel erythropoietin-derived peptide which is not erythropoietic in vivo.